Clinical Trials Logo

Filter by:
NCT ID: NCT05766800 Recruiting - Clinical trials for Non-small Cell Lung Cancer

Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung Cancer

Start date: March 14, 2023
Phase: Phase 2
Study type: Interventional

For unresectable locally-advanced non-small cell lung cancer, chemoradiotherpay plus immunotherapy is recommended by PACIFIC trial. However, it is unclear whether surgery can provide survival benefit for patients with tumors initially unresectable transformed into resectable ones after chemoimmunotherapy. This trial aims to investigate the efficacy and safety of the therapeutic regimen of chemoimmunotherapy plus surgery.

NCT ID: NCT05766605 Recruiting - Clinical trials for Hepatocellular Carcinoma Resectable

Applicability of PDOX in Patients With Primary Liver Cancer: A Randomized Controlled Trial

Start date: January 1, 2023
Phase: Phase 3
Study type: Interventional

This Randomized Controlled Trial was to clarity the clinical feasibility of PDOX results in guiding the drug use of interventional chemotherapy after primary liver cancer surgery.

NCT ID: NCT05766527 Not yet recruiting - Clinical trials for Advanced Solid Tumor

A Study of KM602 in Patients With Advanced Solid Tumors

Start date: April 2023
Phase: Phase 1
Study type: Interventional

This study is a Phase 1 open-label, first-in-human, multicenter study to evaluate the safety, tolerability, pharmacokinetics, and activity of KM602 as monotherapy in patients with advanced solid tumors.

NCT ID: NCT05766462 Recruiting - Clinical trials for Sinus Node Dysfunction

Allometric-Pace Study

Start date: March 20, 2023
Phase:
Study type: Observational

The goal of this observational study is to improve quality of life in sinus node dysfunction patients by utilizing allometric lower rate pacing (or called personalized lower rate, PLR) in standard commercially available dual-chamber pacemakers. The primary objective is to achieve a significant improvement in patients' quality of life with use of PLR pacing in comparison with the control group with nominal lower rate in patients with implanted dual-chamber pacemaker. The secondary objectives are to assess cardiac functional changes in echocardiography of ventricular mechanical performance with a PLR pacing in comparison with the control group with nominal lower rate, and to assess the viability of using elevated blood pressure as a marker for undetected bradycardia and providing allometric rate to correct bradycardia-related increase in arterial systolic blood pressure.

NCT ID: NCT05766449 Recruiting - Clinical trials for Non-alcoholic Fatty Liver Disease

Risk Factors for Hepatic Inflammation, Fibrosis and Prognosis in Patients With CHB and NAFLD

Start date: June 1, 2022
Phase:
Study type: Observational

Chronic hepatitis B (CHB) affects an estimated 292 million people, and causes approximately 800,000 people deaths per year from liver-related complications including cirrhosis and hepatocellular carcinoma, remaining a major global public health issue.Meanwhile, with the improvement of living standards and changes in lifestyle and dietary habits, non-alcoholic fatty liver disease (NAFLD) has become another important cause of liver cirrhosis and HCC.HBV combined with NAFLD inevitably develops into continuous or intermittent liver inflammation and fibrosis, which greatly increases the risk of cirrhosis, liver cancer and even end-stage liver disease. We aimed to investigate the risk factors and establish diagnostic models for hepatic inflammation, fibrosis in patients with CHB associated NAFLD. In addition, to find risk factors for liver cirrhosis, liver cancer or liver failure in patients with CHB-related NAFLD.

NCT ID: NCT05765981 Recruiting - Clinical trials for Aromatic L-amino Acid Decarboxylase (AADC) Deficiency

An Early Clinical Trial to Evaluate VGN-R09b for Treatment of Aromatic L-amino Acid Decarboxylase (AADC) Deficiency.

Start date: January 30, 2023
Phase: Early Phase 1
Study type: Interventional

This early Phase trial is to prove the safety and efficacy of VGN-R09b to treat patients with AADC deficiency.

NCT ID: NCT05765968 Not yet recruiting - Infertility Clinical Trials

Cumulative Live Birth After Double Stimulation Protocol Versus Antagonist Protocol for Poor Ovarian Responders

Start date: March 14, 2023
Phase: N/A
Study type: Interventional

To compare the difference in cumulative live birth rates within one year between double stimulations protocol and two-cycle antagonist protocol in poor ovarian responders.

NCT ID: NCT05765877 Not yet recruiting - Clinical trials for Non-Small Cell Lung Cancer(NSCLC)

Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer

Start date: March 2023
Phase: Phase 2
Study type: Interventional

This is a single-arm, exploratory trial to evaluate the efficacy and safety of neoadjuvant WX-0593 in patients with resectable ALK-positive or ROS1- positive non-small cell lung cancer(NSCLC).

NCT ID: NCT05765825 Recruiting - Clinical trials for Extensive-stage Small-cell Lung Cancer

Study of Low-Dose Radiotherapy Concurrent Chemotherapy With Serplulimab for Patients With ES-SCLC

Start date: March 7, 2023
Phase: Phase 2
Study type: Interventional

This is a Phase II, single arm, multicenter study designed to evaluate the safety and efficacy of low-dose radiotherapy (LDRT) concurrent cisplatin/carboplatin plus etoposide with serplulimab in participants who have extensive-stage small cell lung cancer (ES-SCLC) and are chemotherapy-navïe for their extensive-stage disease.

NCT ID: NCT05765760 Recruiting - Clinical trials for Acute Respiratory Distress Syndrome

Improvement of ARDS Ventilation-perfusion Matching by Prone Positioning Assessed by EIT

Start date: April 1, 2023
Phase:
Study type: Observational

Acute Respiratory Distress Syndrome (ARDS) is a highly lethal disease with limited treatment options. In recent years, prone position ventilation has been shown to improve the mortality rate and lung injury of ARDS patients by promoting lung recruitment, improving ventilation/perfusion (V/Q) ratio, enhancing respiratory system compliance, promoting sputum drainage, and effectively avoiding overinflation of the dorsal lung. Electrical Impedance Tomography (EIT) technology has been used to evaluate the effect of prone position ventilation on lung V/Q matching, and some studies have confirmed that prone position ventilation can improve lung V/Q matching and oxygenation index. However, previous studies were mostly case reports or small-sample physiological studies that lacked dynamic changes in lung V/Q matching during repeated prone position ventilation. Therefore, this study hypothesizes that prone position ventilation can increase lung V/Q matching in ARDS patients, and its improvement is correlated with changes in oxygenation index, invasive ventilation time, and patient prognosis. Repeated prone position ventilation can maintain lung V/Q matching at a higher level, no longer affected by changes in body position, which can accelerate pulmonary function recovery and improve the prognosis of ARDS patients.